Stability of Fibroblast Growth Factor 23 in Human Plasma.

BACKGROUND Given the important emerging field of fibroblast growth factor 23 (FGF23) biology, there is a growing need for reliable data on FGF23 assay characteristics. We therefore evaluated the effects of different processing and storage conditions on FGF23 stability, as well as the assay precision of FGF23 measurements using 2 commercially available FGF23 ELISA kits. METHODS We measured plasma concentrations of intact FGF23 (iFGF23) and C-terminal FGF23 (cFGF23) in duplicate in 12 patients with a wide range of kidney function. We used blinded replicate samples to calculate the interassay CV for both assays. We processed the samples immediately after collection, after 6 h at 22 °C, or after 24 h at 4 °C. We also exposed samples to 0, 1, 2, or 3 freeze-thaw cycles. RESULTS The interassay CVs for iFGF23 and cFGF23 were 5.2% and 7.2%, respectively. Delayed processing for either 6 h at 22 °C or 24 h at 4 °C had no significant effect on either iFGF23 or cFGF23, although a nonsignificant trend toward decreased iFGF23 concentrations was observed compared with immediate processing (23% relative decline in concentrations under both delayed processing conditions). Three freeze-thaw cycles had no effect on either iFGF23 or cFGF23 concentrations. CONCLUSIONS FGF23 measurements in human plasma are stable with delayed processing or after undergoing multiple freeze-thaw cycles.

[1]  M. Wolf,et al.  Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. , 2016, Kidney international.

[2]  A. Go,et al.  Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study. , 2016, JAMA cardiology.

[3]  C. DeCarli,et al.  Fibroblast Growth Factor 23 Is Associated With Subclinical Cerebrovascular Damage: The Northern Manhattan Study , 2016, Stroke.

[4]  M. Unruh,et al.  FGF23 signaling impairs neutrophil recruitment and host defense during CKD. , 2016, The Journal of clinical investigation.

[5]  P. Andreopoulou,et al.  Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type , 2016, Osteoporosis International.

[6]  Edward R. Smith,et al.  Fibroblast growth factor 23 , 2014, Annals of clinical biochemistry.

[7]  Edward R. Smith,et al.  Method-specific differences in plasma fibroblast growth factor 23 measurement using four commercial ELISAs , 2013, Clinical chemistry and laboratory medicine.

[8]  A. Go,et al.  FGF23 induces left ventricular hypertrophy. , 2011, The Journal of clinical investigation.

[9]  Jiang He,et al.  Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. , 2011, JAMA.

[10]  Edward R. Smith,et al.  Instability of fibroblast growth factor-23 (FGF-23): implications for clinical studies. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[11]  Thomas J. Wang,et al.  Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease , 2009, Circulation.

[12]  V. Brandenburg,et al.  Evaluation of human fibroblast growth factor 23 (FGF-23) C-terminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patients. , 2009, Clinical laboratory.

[13]  S. Mundra,et al.  Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis , 2009 .

[14]  Y. Takeuchi,et al.  FGF‐23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.